UK Companies House feature
CYCLE GROUP HOLDINGS LIMITED
Profile
- Company number
- 12708790
- Status
- Active
- Incorporation
- 2020-06-30
- Last accounts made up
- 2024-12-31
- Account category
- GROUP
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- IFRS
- Reporting scope
- Consolidated (group)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Group is a profitable and cash generative pharmaceutical company, delivering revenue growth of 32% to $133,493k, Operating Profit of $41,049k and had net cash at 31 December 2024 of $58,544k. Management has prepared a cash flow forecast for a twelve-month period following the approval of the financial statements, showing continued growth of the business, which will enable the Group to continue as a going concern.”
Subsidiaries
- Cycle Pharmaceuticals Ltd · 100% held · United Kingdom · Development of pharmaceutical products
- Cycle Pharmaceuticals Incorporated · 100% held · USA · Promotion of pharmaceutical products and patient support
- Varsity Pharmaceuticals Limited · 100% held · United Kingdom · Inactive
- Cycle Pharmaceuticals (Europe) Limited · 100% held · Ireland · Dormant
Significant events
- “On 10 January 2025, the Group purchased 100% of the shares of Banner Life Sciences LLC for upfront consideration of $51.6m, funded from cash on hand.”
- “On 18 March 2025, a new branded generic product VENXXIVA was launched in the US market.”
- “On 28 March 2025, the Group signed a Revolving Credit Facility, providing the Group with $100m of borrowing capacity.”
- “On 3 April 2025, the Group repaid all outstanding amounts due under the Deutsche Bank loan ($14.5m) and repurchased for cancellation all remaining warrants for $5m.”
- “On 18 April 2025, the Group signed a commercialisation agreement with Handa Pharma to commercialise PHYRAGO in the US, an approved treatment for rare forms of leukaemia.”
- “On 9 May 2025, the Group signed a commercialisation agreement with Lupin Inc to launch a branded generic form of glycerol phenylbutyrate.”
- “On 10 June 2025 the FDA approved HARLIKU (nitisinone) for the treatment of Alkaptonuria (AKU) a rare, inherited, metabolic disorder.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
7 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| REINER, Andrea Curti | Secretary | 2025-11-13 | — | — |
| BUCKERIDGE, David James | Director | 2020-09-09 | Feb 1960 | British |
| CATES, Antony George | Director | 2021-09-24 | Mar 1966 | British |
| HARRISON, James Alexander | Director | 2020-06-30 | Feb 1974 | British |
| MOORE, Duncan Charles Mcnaught | Director | 2020-07-07 | Jan 1959 | British |
| REASON, Ross George | Director | 2025-08-01 | May 1961 | British |
| ROBINSON, William John | Director | 2020-07-07 | Feb 1948 | British |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GOWING, Sarah Jean | Secretary | 2021-08-01 | 2025-11-13 |
| BRUNA, Alejandra, Dr | Director | 2021-04-01 | 2024-04-01 |
| REASON, Ross George | Director | 2020-07-07 | 2024-09-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mr James Alexander Harrison | Individual | Shares 50–75%, Voting 50–75%, Appoints directors | 2020-06-30 | Active |
Filing timeline
Last 20 of 80 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-22 | SH03 | capital | capital return purchase own shares |
| 2026-04-02 | SH06 | capital | capital cancellation shares |
| 2026-03-18 | SH01 | capital | capital allotment shares |
| 2026-02-19 | SH01 | capital | capital allotment shares |
| 2025-12-09 | SH01 | capital | capital allotment shares |
| 2025-12-08 | SH03 | capital | capital return purchase own shares |
| 2025-11-14 | SH06 | capital | capital cancellation shares |
| 2025-11-13 | AP03 | officers | appoint person secretary company with name date |
| 2025-11-13 | TM02 | officers | termination secretary company with name termination date |
| 2025-11-12 | SH01 | capital | capital allotment shares |
| 2025-10-21 | SH01 | capital | capital allotment shares |
| 2025-08-13 | AA | accounts | accounts with accounts type group |
| 2025-08-01 | AD01 | address | change registered office address company with date old address new address |
| 2025-08-01 | AP01 | officers | appoint person director company with name date |
| 2025-07-07 | SH03 | capital | capital return purchase own shares |
| 2025-07-01 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-06-21 | MR04 | mortgage | mortgage satisfy charge full |
| 2025-06-16 | SH06 | capital | capital cancellation shares |
| 2025-06-05 | SH01 | capital | capital allotment shares |
| 2025-04-08 | MR04 | mortgage | mortgage satisfy charge full |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.